From RuntimeWire · RuntimeWire · · 30s
Maxwell's pneumonia drug gets FDA QIDP status
Maxwell's experimental pneumonia drug receives FDA Qualified Infectious Disease Product designation.
In brief
Maxwell's experimental pneumonia drug receives FDA Qualified Infectious Disease Product designation. Maxwell Biosciences' preclinical pneumonia drug received FDA QIDP status in May, advancing its regulatory path. Originally reported by RuntimeWire.
FDA QIDP designation
Maxwell Biosciences' experimental pneumonia drug received FDA Qualified Infectious Disease Product status in May.
Preclinical status
The candidate remains preclinical and has not been tested in people.
Regulatory development path
The designation gives Maxwell a regulatory development path.
The takeaway
Maxwell Biosciences' preclinical pneumonia drug received FDA QIDP status in May, advancing its regulatory path.
